Pyridine‐2(1H)‐thiones were used to prepare two novel series of nicotinonitriles and thieno[2,3‐b]pyridines using piperazine as an eco‐friendly catalyst and under ultrasonic irradiation. The in vitro antibacterial activities of both series were estimated against different Gram‐positive and negative bacterial strains. 2‐((4‐(Benzo[d][1,3]dioxol‐5‐yl)‐3‐cyano‐6‐(thiophen‐2‐yl)pyridin‐2‐yl)thio)acetamide (13 b) gave the least MIC/MBC values of 4.8/9.6, 4.8/9.6 and 9.6/19.7 μM against each of Staphylococcus aureus, Escherichia coli and Streptococcus mutans, respectively, when compared with Ciprofloxacin. Compound 13 b showed also the best biofilm inhibition activities with IC50 values in the range of 5.2‐7.3 μM against S. aureus, S. mutans and E. coli bacterial strains when compared with Ciprofloxacin. Moreover, the most potent antibacterial derivatives were subjected to further evaluation of their cytotoxic activity against HEPG2 and MCF‐7 cell lines as well as their capability to inhibit COX‐2 enzyme. 13 b exhibited the best cytotoxic activity against HEPG2 and MCF‐7 cell lines with IC50 of 23.9 and 29.8 μM, respectively, when compared with Doxorubicin. Also, 13 b revealed nearly inhibition activity equipotent to Celecoxib with IC50 of 0.12 μM. The in silico study was performed to predict the capability of the novel nicotinonitriles and thienopyridines as potent inhibitors of COX‐2 enzyme.